The encouraging results in the ICI therapy of the CD73-/- mouse model of GBM along with the roles of AP in the NK cells could promise the combination of AP-targeting methods with ICI and NK cell therapy [59,104]. This evidence concerns the gene NT5E and glioblastoma.